Evaluación de la indicación, consumo y costos de antifúngicos en un hospital pediátrico de Chile

Barraza, Marlon; Barnafi, Natalia; Ortíz, Guillermo; Torres, Juan Pablo; Coria, Paulina; Catalán, Paula; Palma, Julia; Morales, Jorge

doi:10.4067/s0716-10182018000400351

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The costs related to long-term antifungal prophylaxis for the patient and the healthcare system should be considered as well, because cumulative antifungal drug-costs over time may amount to several thousand dollars per patient. [50][51][52][53] Moreover, costs of hospital admissions associated with drug side effects should also be taken into account, and costs may furthermore vary greatly per country and per center. However, because of the lack of data about direct comparisons of the efficacy of these antifungal agents as such, and regarding the pharmaco-economic cost-benefit of azoles for antifungal prophylaxis after LTx in particular, no clear recommendations concerning costeffectiveness can be made.…”

Section: Costs Of Antifungal Prophylaxismentioning

confidence: 99%

Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?

et al. 2021

View full text Add to dashboard Cite

BackgroundLung transplantation is an important treatment option for various end-stage lung diseases. However, survival remains limited due to graft rejection and infections. Despite that fungal infections are frequent and carry a bad prognosis, there is currently no consensus on efficacy, optimal drug, route or duration of antifungal prophylaxis. This narrative review summarizes current strategies for antifungal prophylaxis after lung transplantation. MethodsEnglish-language articles in Embase, Pubmed, UptoDate and bibliographies were used to assess efficacy and safety of available antifungal agents for prophylaxis in adult lung transplant recipients. ResultsOverall, there are limited high quality data. Universal prophylaxis is more widely used and may be preferable over targeted prophylaxis. Both formulations of inhaled amphotericin B and systemic azoles are effective at reducing fungal infection rates, yet with their own specific advantages and disadvantages. The benefit of combination regimens has yet to be proven.Considering the post-transplant timing of onset of fungal infections, postoperative prophylaxis during the first postoperative months seems indicated for most patients. ConclusionsBased on existing literature, universal antifungal prophylaxis with inhaled amphotericin B and/or systemic voriconazole for at least 3 to 6 months after lung transplantation may be advisable, with a slight preference for amphotericin B because of its better safety profile.

show abstract

Section: Costs Of Antifungal Prophylaxismentioning

confidence: 99%

Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?

et al. 2021

View full text Add to dashboard Cite

show abstract

Aspergilosis: Casuística del Laboratorio Central de Salud Pública-Ministerio de Salud. Asunción, Paraguay. Período 2000 – 2019

Aguilar-Fernández,

Araujo-López,

Lird

et al. 2025

Iatreia

View full text Add to dashboard Cite

Introducción: la aspergilosis es una micosis oportunista con gran impacto en pacientes Inmunodeprimidos; los datos disponibles en Paraguay son escasos. Objetivos: caracterizar a los pacientes con diagnóstico de aspergilosis cuyas muestras fueron enviadas a la sección de Micología del Laboratorio Central de Salud Pública en el período 2000-2019. Materiales y métodos: estudio descriptivo y retrospectivo de fichas de pacientes con muestras positivas del género Aspergillus. Resultados: se encontraron 54 pacientes con diagnóstico de aspergilosis: Otomicosis 21 (38,9 %), aspergilosis pulmonar crónica 17 (31,5 %), sinusitis aguda y crónica 5 (9,2 %), aspergilosis invasiva 4 (7,4 %), onicomicosis 3 (5,6 %), aspergilosis broncopulmonar alérgica 2 (3,7 %) y queratitis 2 (3,7 %). Los aislamientos fueron 56: Aspergillus sección Fumigati 26 (46,4 %), A. sección Flavi 15 (26,8 %), A. sección Nigri 13 (23,2 %), A. sección Terrei 1 (1,8 %) y Aspergillus glaucus 1 (1,8 %). Los métodos de diagnóstico microbiológico fueron el examen en fresco, coloraciones, cultivo y serología. Conclusiones: en un período de 20 años varios casos de aspergilosis fueron informados. La otomicosis con predominio en adultos fue la forma de aspergilosis prevalente. En las formas crónicas rino-pulmonares la tuberculosis, tumores, enfermedad obstructiva crónica, fibrosis quísticas y asma fueron los factores predisponentes. La aspergilosis invasiva fue de preferencia en pediatría donde las enfermedades autoimunes y leucemias fueron los factores de riesgo. Aspergillus sección Fumigati fue prevalente del total de aislamientos seguido de Aspergillus sección Flavi y Aspergillus sección Nigri.

show abstract

Evaluación de la indicación, consumo y costos de antifúngicos en un hospital pediátrico de Chile

Abstract: Los autores declaran no tener conflicto o interés financiero en cualquier producto o servicio mencionado en el manuscrito, incluyendo subvenciones, equipo, medicamentos, empleo, regalos y honorarios.

Cited by 2 publications

References 16 publications

Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?

Antifungal Prophylaxis After Lung Transplantation: Where Are We Now?

Aspergilosis: Casuística del Laboratorio Central de Salud Pública-Ministerio de Salud. Asunción, Paraguay. Período 2000 – 2019

Contact Info

Product

Resources

About